RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals to $424 from $417 but keeps a Sector Perform rating on the shares. The company reported an “optically sound” Q1 with worldwide sales exceeding expectations, though this was driven mainly by ex-U.S. growth that encompassed some inventory benefits, while its U.S. sales were down sequentially, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Options Volatility and Implied Earnings Moves Today, May 06, 2024
- Options Volatility and Implied Earnings Moves This Week, May 06 – May 10, 2024
- VRTX Earnings this Week: How Will it Perform?
- Vertex announces European Commission approval for KALYDECO
- Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call